Johnson & Johnson's Caplyta (lumateperone) met the primary endpoint in the Phase 3 Study 451, cutting Young Mania Rating Scale scores by 4.8 points more than placebo at Week 3 with separation by Day 3. Clinical response reached 45.8% versus 20.9% on placebo. The drug is not yet approved for bipolar I mania; a second pivotal trial, Study 452, is complete and under analysis.
A once-daily 42 mg dose of lumateperone (Caplyta) beat placebo on manic symptoms in adults with bipolar I disorder, delivering a 4.8-point greater drop in Young Mania Rating Scale total score at Week 3, Johnson & Johnson said.
The Phase 3 Study 451 randomized adults experiencing manic episodes, with or without mixed features, to lumateperone or placebo for three weeks. The effect size was −0.69 at a p-value below .0001, and the between-group difference reached statistical significance as early as Day 3 and held through the end of the study.
"Mania is among the most dangerous and worrisome phases of bipolar disorder, and treating it effectively takes more than partial or temporary relief of symptoms; it means bringing the episode itself under control as quickly as possible," said Michael E. Thase, professor of psychiatry and chief of the Division of Mood and Anxiety Disorders Treatment & Research Program at the University of Pennsylvania, who has consulted for Johnson & Johnson. "These results are encouraging because Caplyta not only significantly improved the symptoms of mania, but did so as early as Day 3, with benefits sustained through Week 3."
Clinical response, defined as a reduction of at least 50% in YMRS total score, was achieved by 45.8% of lumateperone-treated participants versus 20.9% on placebo, a p-value below .0001. On the Clinical Global Impression–Severity scale, a key secondary endpoint, the least-squares mean difference favoring lumateperone was −0.5, also at a p-value below .0001.
Treatment-related adverse events reported in at least 5% of the lumateperone group and at least twice the placebo rate were dry mouth, at 7.9% versus 3.4%, and nausea, at 7.9% versus 2.3%. Johnson & Johnson described discontinuation rates as low but did not publish numerical rates or a full adverse-event table. The drug carries class warnings for tardive dyskinesia, neuroleptic malignant syndrome, metabolic changes, leukopenia and orthostatic hypotension; no new safety signal was flagged in Study 451.
The topline results were released Sept. 21 and presented as a late-breaking poster at Psych Congress 2026 in New Orleans, one of 24 Johnson & Johnson neuropsychiatry presentations at the meeting. Lumateperone is already cleared in the US for depressive episodes associated with bipolar I or II disorder, for schizophrenia, and as adjunctive therapy for major depressive disorder. It is not approved for manic episodes associated with bipolar I disorder.
That gap is the commercial question. Bipolar disorder affects an estimated 37 million people worldwide, and mania is the phase most likely to require hospitalization. A single oral agent covering both the depressive and manic poles would compete against lithium, valproate and atypicals including olanzapine, quetiapine, aripiprazole and AbbVie's Vraylar (cariprazine) — a crowded field where lumateperone's low metabolic burden is the main differentiator.
Johnson & Johnson acquired Intra-Cellular Therapies, lumateperone's originator, for $14.6 billion in early 2025, with multi-indication expansion of Caplyta central to the deal's rationale. The company said it plans to discuss data from both Study 451 and Study 452 with regulators to determine next steps on a mania filing. Study 452 has been completed and is undergoing analysis.
The readout supports a regulatory submission but does not establish comparative effectiveness against an active antimanic treatment, and the three-week duration leaves maintenance efficacy, relapse prevention and longer-term metabolic effects unmeasured. Full peer-reviewed results, including enrollment, subgroup and comprehensive safety data, have not been published.
For holders, the signal is that the Intra-Cellular acquisition is producing label-expansion optionality rather than a single-indication asset, though the revenue contribution depends on an approval that has not been filed. The next checkpoint is Study 452's analysis, which Johnson & Johnson has not dated, followed by any FDA filing decision.
This article is for informational purposes only and does not constitute investment advice.
